Somaxon Pharmaceuticals, Inc.
http://www.somaxon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Somaxon Pharmaceuticals, Inc.
Q1 2024 Posts Big M&A Total Led By Novo Holdings’ Catalent Takeout
The $16.5bn deal, intended to increase Novo Nordisk’s production of semaglutide-containing products, led a $36bn-plus quarter for M&A transactions, according to Evaluate.
PRIME Scheme: EMA Says Yes To Hookipa, Bluejay & 89bio But No To Six Others
Esepapogene zalarnarepvec, BJT-778 and pegozafermin are the latest investigational products that the European Medicines Agency said merited a place on its priority medicines scheme.
Almirall Casts Its Net To Cover Butterfly Skin Disease
Deal Snapshot: The Spanish company is linking up with US biotech Eloxx to get hold of an asset that will be its first in the rare dermatological disease space.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice